A novel in vitro model of metastasis supporting passive shedding hypothesis from murine pancreatic cancer Panc-02.
Cancer model
In vitro metastatic selection
Panc-02
Pancreatic cancer metastasis
passive sheding mechanism
Journal
Cytotechnology
ISSN: 0920-9069
Titre abrégé: Cytotechnology
Pays: United States
ID NLM: 8807027
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
19
01
2019
accepted:
21
08
2019
pubmed:
11
9
2019
medline:
11
9
2019
entrez:
11
9
2019
Statut:
ppublish
Résumé
Cancer metastasis is believed to happen through active intravasation but there might be also another way to metastasize. According to passive shedding hypothesis, proposed by Munn et al., tumor cells detach from the tumor mass and passively shed to blood stream through leaky blood vessels. We propose a novel In Vitro Migrational Selection (IVMS) assay that enables the pre-selection of invasive pancreatic cancer Panc-02 cells and create a model of passive shedding. We established invasive sub-cell line of murine pancreatic cancer Panc-02 cells (refered to as Panc02-RS), which exhibited higher metastatic potential in vivo and at the same time decrease in vitro migratory skills, comparing to the initial Panc-02 cell line. In in vitro cell cultures Panc-02 spontaneously detached from the cell culture surface and later reattached and colonized new areas. We believe it can mimic the new way of metastasis, namely passive shedding. We concentrated on Panc-02 model but believe that IVMS might be used to create sub cell lines of many solid tumors to model passive shedding. Our results support the passive shedding hypothesis.
Identifiants
pubmed: 31502069
doi: 10.1007/s10616-019-00341-2
pii: 10.1007/s10616-019-00341-2
pmc: PMC6787126
doi:
Types de publication
Journal Article
Langues
eng
Pagination
989-1002Subventions
Organisme : Fundacja na rzecz Nauki Polskiej (PL)
ID : VENTURES/2010-6/5
Organisme : Fundacja na rzecz Nauki Polskiej (PL)
ID : 174/UD/SKILLS/2012
Références
Cancer Res. 1975 Mar;35(3):512-6
pubmed: 1090362
Cancer Res. 1976 Mar;36(3):889-94
pubmed: 1253177
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cancer Res. 1993 Aug 1;53(15):3475-85
pubmed: 8393376
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33
pubmed: 15217949
Mol Cancer. 2003 Jan 22;2:14
pubmed: 12605717
Neoplasia. 1999 Apr;1(1):50-62
pubmed: 10935470
Phys Biol. 2009 Mar 25;6(1):016008
pubmed: 19321920
Integr Biol (Camb). 2016 Dec 5;8(12):1232-1245
pubmed: 27761545
Int J Gastrointest Cancer. 2001;29(1):25-36
pubmed: 12754402
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Cell Cycle. 2006 Apr;5(8):812-7
pubmed: 16627996
Clin Cancer Res. 1999 Nov;5(11):3711-21
pubmed: 10589791
Cancer Res. 2016 Aug 15;76(16):4595-7
pubmed: 27528578
Lancet Oncol. 2007 May;8(5):444-8
pubmed: 17466902
J Biomol Tech. 2010 Sep;21(3):120-5
pubmed: 20808641
Folia Med Cracov. 2015;55(3):15-24
pubmed: 26774804
Mol Pharm. 2011 Feb 7;8(1):12-28
pubmed: 21126047
Cancer Cell. 2013 Oct 14;24(4):410-21
pubmed: 24135279
Cancer Res. 1984 Feb;44(2):717-26
pubmed: 6692374
Clin Transl Med. 2015 Apr 14;4:14
pubmed: 25932287
PLoS One. 2017 Jun 20;12(6):e0179862
pubmed: 28632775